Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
暂无分享，去创建一个
Marilyn M. Li | S. Hilsenbeck | R. Schiff | J. Reis-Filho | B. Weigelt | Jenny C. Chang | A. Wolff | M. Goetz | R. Nanda | A. Pavlick | Tao Wang | A. Forero | I. Mayer | C. Kent Osborne | K. Burke | I. Krop | A. Contreras | F. Geyer | C. De Angelis | C. Gutierrez | M. Rimawi | F. Pareja | S. Fuqua | S. Herrera